Abstract 1130P
Background
Tebe, a bispecific T-cell engager, showed a benefit in response rate, progression-free survival (PFS) and overall survival (OS) in HLA A*02-01pos mUM pts in the IMCgp100-202 phase III trial. Prior to approval, French Health Authorities allowed an early access to Tebe in May 2021 to mUM pts. We report here our real-world experience with Tebe and analyses of potential prognostic and predictive biomarkers.
Methods
Ongoing ambispective cohort of mUM pts treated with Tebe. Tumor sizes were evaluated according to RECIST 1.1. Circulating tumor DNA (ctDNA) analyses were performed on this cohort and on the 18 pts enrolled in the IMCgp100-202 trial and randomized to Tebe, at Institut Curie. ctDNA was measured by digital droplet PCR (ddPCR) targeting codons 183 & 209 of both GNAQ and GNA11.
Results
72 pts were included from May 26th 2021 to December 12th 2022. With a median follow-up of 48 weeks, patients received a median of 22 weeks of Tebe. Out of 60 assessable pts, 33 (55%) showed stable disease and 5 (8%) partial response according to RECIST 1.1. Median PFS (mPFS) was 28 weeks (confidence interval 95% [CI95]: 8-56). OS at 12 months (OS12m) was 72%. No new, unexpected safety event occurred. Elevated baseline LDH was correlated with poorer OS (Spearman rho= -0.26, p<0.01). 63 pts had mUM carrying somatic mutations detectable by ddPCR (ie GNAQ/GNA11 mutations). Of these, 39 pts (62%) had detectable ctDNA at baseline. Pts with detectable ctDNA at baseline had poorer PFS (mPFS 4.0 vs 14.0 months; HR=2.83, CI95[1.48-5.41]) and OS (OS12m of 51.5% vs 95.4%; HR=6.11, CI95[2.04-18.3]) than those with undetectable ctDNA. 22 pts cleared their ctDNA at first assessment (12 weeks) and had numerically better OS12m than those who did not (70% vs 60%; HR = 1.83 CI95[0.92-13.9]).
Conclusions
In this real-world cohort of mUM pts, Tebe is associated with clinical outcomes in lin withthe IMCgp100-202 trial. Baseline ctDNA and LDH are prognostic factors while ctDNA clearance might predict benefit from Tebe. Other analyses are ongoing to identify new predictive biomarkers.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
INSERM.
Disclosure
M. Saint-Ghislain: Financial Interests, Invited Speaker: Oncotream. J. Thery: Financial Interests, Invited Speaker: PharmaMar; Financial Interests, Advisory Board: Pfizer, AstraZeneca. P. Combe: Financial Interests, Invited Speaker: Eisai, BMS GmbH&Co.KG, Novartis, Clovis Oncology, AstraZeneca. C. Dutriaux: Financial Interests, Advisory Board: Bristol Myers Squibb, MSD, Pierre Fabre. S. Piperno-Neumann: Financial Interests, Personal, Advisory Board: Immunocore, Pierre Fabre, Atlanthera. M.J. Rodrigues: Financial Interests, Personal, Invited Speaker: Immunocore; Financial Interests, Personal, Advisory Board: GSK, AstraZeneca; Financial Interests, Institutional, Coordinating PI: Johnson & Johnson; Non-Financial Interests, Institutional, Product Samples: MSD. All other authors have declared no conflicts of interest.
Resources from the same session
1150P - Transforming growth factor-beta-1 and soluble co-inhibitory immune checkpoints as putative drivers of immune suppression in advanced basal cell carcinoma
Presenter: Bernardo Rapoport
Session: Poster session 13
1151P - Characteristics and treatment outcomes in cutaneous adnexal carcinomas
Presenter: Adam Rock
Session: Poster session 13
1152P - Association of immune-related adverse events (irAE) requiring glucocorticoids (GCs) with outcome and biomarkers in advanced cutaneous malignant melanoma (CMM) treated with immune checkpoint inhibitors (ICI)
Presenter: Fernanda Costa Svedman
Session: Poster session 13
1153P - Incidence and characteristics of immunotherapy related adrenal insufficiency in a monocenter, pan-cancer cohort of 4314 patients
Presenter: Minke Lucas
Session: Poster session 13
1154P - Thromboembolic events in patients with melanoma receiving immune checkpoint inhibitors: Incidence and risk factors
Presenter: Daan van Dorst
Session: Poster session 13
1155P - Application of novel machine learning to predict immunotherapy related toxicities for metastatic melanoma patients from baseline 18F-FDG PET/CT scans
Presenter: Roslyn Francis
Session: Poster session 13
1156P - Immune-related adverse events in a nationwide cohort of melanoma patients treated with adjuvant anti-PD1: Seasonal variation and association with outcome
Presenter: Eva Ellebæk
Session: Poster session 13
1157P - Corticosteroids and second-line immunosuppressants for immune-related adverse events and melanoma survival
Presenter: Rik Verheijden
Session: Poster session 13
1158P - Association of corticosteroid (CS) exposure with treatment failure in patients (pts) with advanced melanoma treated with immune checkpoint inhibitors (ICIs)
Presenter: Ha Mo Linh Le
Session: Poster session 13
1159P - Characterization of melanoma of unknown primary in the era of immunotherapy and targeted therapy in Spain: Results from the prospective real-world study GEM 1801
Presenter: Pablo Cerezuela-Fuentes
Session: Poster session 13